AUPR177300A0 - Therapeutic methods - Google Patents

Therapeutic methods

Info

Publication number
AUPR177300A0
AUPR177300A0 AUPR1773A AUPR177300A AUPR177300A0 AU PR177300 A0 AUPR177300 A0 AU PR177300A0 AU PR1773 A AUPR1773 A AU PR1773A AU PR177300 A AUPR177300 A AU PR177300A AU PR177300 A0 AUPR177300 A0 AU PR177300A0
Authority
AU
Australia
Prior art keywords
treatment
relates
uridine
therapy
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR1773A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre for Molecular Biology and Medicine
Original Assignee
Centre for Molecular Biology and Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre for Molecular Biology and Medicine filed Critical Centre for Molecular Biology and Medicine
Priority to AUPR1773A priority Critical patent/AUPR177300A0/en
Publication of AUPR177300A0 publication Critical patent/AUPR177300A0/en
Priority to NZ526069A priority patent/NZ526069A/en
Priority to HK04101929.0A priority patent/HK1059044B/en
Priority to AU2002223302A priority patent/AU2002223302B2/en
Priority to EP01998341A priority patent/EP1343488B1/en
Priority to JP2002545692A priority patent/JP4596734B2/ja
Priority to DE60130023T priority patent/DE60130023T2/de
Priority to AU2330202A priority patent/AU2330202A/xx
Priority to AT01998341T priority patent/ATE369845T1/de
Priority to US10/433,074 priority patent/US20040063661A1/en
Priority to CA2429979A priority patent/CA2429979C/en
Priority to PCT/AU2001/001545 priority patent/WO2002043721A1/en
Priority to ES01998341T priority patent/ES2292643T3/es
Priority to US12/706,257 priority patent/US20100144665A1/en
Priority to JP2010151665A priority patent/JP2010248230A/ja
Priority to US12/849,943 priority patent/US20100323981A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPR1773A 2000-11-29 2000-11-29 Therapeutic methods Abandoned AUPR177300A0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AUPR1773A AUPR177300A0 (en) 2000-11-29 2000-11-29 Therapeutic methods
ES01998341T ES2292643T3 (es) 2000-11-29 2001-11-29 Tratamiento de los efectos colaterales de la estatina.
DE60130023T DE60130023T2 (de) 2000-11-29 2001-11-29 Behandlung der nebenwirkungen von statinen
AT01998341T ATE369845T1 (de) 2000-11-29 2001-11-29 Behandlung der nebenwirkungen von statinen
AU2002223302A AU2002223302B2 (en) 2000-11-29 2001-11-29 Treatment of statin side effects
EP01998341A EP1343488B1 (en) 2000-11-29 2001-11-29 Treatment of statin side effects
JP2002545692A JP4596734B2 (ja) 2000-11-29 2001-11-29 スタチン副作用の処置
NZ526069A NZ526069A (en) 2000-11-29 2001-11-29 Treatment of statin side effects
AU2330202A AU2330202A (en) 2000-11-29 2001-11-29 Treatment of statin side effects
HK04101929.0A HK1059044B (en) 2000-11-29 2001-11-29 Treatment of statin side effects
US10/433,074 US20040063661A1 (en) 2000-11-29 2001-11-29 Treatment of statin side effects
CA2429979A CA2429979C (en) 2000-11-29 2001-11-29 Treatment of statin side effects
PCT/AU2001/001545 WO2002043721A1 (en) 2000-11-29 2001-11-29 Treatment of statin side effects
US12/706,257 US20100144665A1 (en) 2000-11-29 2010-02-16 Treatment of statin side effects
JP2010151665A JP2010248230A (ja) 2000-11-29 2010-07-02 スタチン副作用の処置
US12/849,943 US20100323981A1 (en) 2000-11-29 2010-08-04 Treatment of statin side effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR1773A AUPR177300A0 (en) 2000-11-29 2000-11-29 Therapeutic methods

Publications (1)

Publication Number Publication Date
AUPR177300A0 true AUPR177300A0 (en) 2000-12-21

Family

ID=3825810

Family Applications (3)

Application Number Title Priority Date Filing Date
AUPR1773A Abandoned AUPR177300A0 (en) 2000-11-29 2000-11-29 Therapeutic methods
AU2330202A Pending AU2330202A (en) 2000-11-29 2001-11-29 Treatment of statin side effects
AU2002223302A Ceased AU2002223302B2 (en) 2000-11-29 2001-11-29 Treatment of statin side effects

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2330202A Pending AU2330202A (en) 2000-11-29 2001-11-29 Treatment of statin side effects
AU2002223302A Ceased AU2002223302B2 (en) 2000-11-29 2001-11-29 Treatment of statin side effects

Country Status (10)

Country Link
US (3) US20040063661A1 (enExample)
EP (1) EP1343488B1 (enExample)
JP (2) JP4596734B2 (enExample)
AT (1) ATE369845T1 (enExample)
AU (3) AUPR177300A0 (enExample)
CA (1) CA2429979C (enExample)
DE (1) DE60130023T2 (enExample)
ES (1) ES2292643T3 (enExample)
NZ (1) NZ526069A (enExample)
WO (1) WO2002043721A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR951101A0 (en) * 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
WO2004105742A1 (en) * 2003-06-02 2004-12-09 Isis Innovation Limited Treatment of muscle fatigue
US20060280721A1 (en) 2003-06-03 2006-12-14 The Gov Of Usa Represented By Secretary Of Dpt Of Nutritional supplements and therapeutic compositions comprising (r)-3- hydroxybutyrate derivatives
ES2631152T3 (es) 2004-01-22 2017-08-28 University Of Miami Formulaciones de coenzima Q10 tópicas o intravenosas para su uso en el tratamiento del cáncer
EP1784172A4 (en) * 2004-06-21 2007-12-19 Hutchison Medipharma Entpr Ltd CANCER CHEMOTHERAPY
WO2006009840A1 (en) * 2004-06-21 2006-01-26 Hutchison Medipharma Enterprises Limited Benzoquinone compounds as a anti-cancer agents
JP4896501B2 (ja) * 2004-11-26 2012-03-14 第一三共株式会社 血中遊離脂肪酸低下作用を有する医薬組成物
WO2006057209A1 (ja) * 2004-11-26 2006-06-01 Sankyo Company, Limited 血中遊離脂肪酸低下作用を有する医薬組成物
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
EP2564843B1 (en) 2005-06-01 2018-12-26 Bioelectron Technology Corporation Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
WO2007127908A2 (en) * 2006-04-28 2007-11-08 Hutchison Medipharma Enterprises Limited Dihydrobenzoquinone compounds
ES2836184T3 (es) * 2006-05-02 2021-06-24 Univ Miami Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
CN106038532B (zh) 2008-01-04 2019-05-14 牛津大学科技创新有限公司 用作降低血脂药剂的酮体和酮体酯
KR101686917B1 (ko) 2008-02-29 2016-12-15 바이오랩 세너스 팔마씨우티카 엘티디에이. 라세탐 및 카르니틴을 포함하는 약학 조성물 및 그의 제조방법
EP2271325A4 (en) 2008-04-11 2011-11-09 Cytotech Labs Llc METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS
US8642654B2 (en) 2009-04-16 2014-02-04 Isis Innovation Limited Hydroxybutyrate ester and medical use thereof
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
GB201002983D0 (en) 2010-02-22 2010-04-07 Tdeltas Ltd Nutritinal composition
EP2694463B8 (en) 2011-04-04 2019-10-09 Berg LLC Treating central nervous system tumors with coenzyme q10
MX2014001823A (es) 2011-08-15 2014-08-21 Technion Res & Dev Foundation Combinaciones de corroles y estatinas.
TWI489982B (zh) * 2012-09-18 2015-07-01 Univ China Medical 苯醌類化合物應用於抑制動脈粥狀血管硬化之用途
TWI504390B (zh) * 2012-09-18 2015-10-21 Univ China Medical 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
DK2914251T3 (da) 2012-11-05 2019-11-04 Us Health Ketonlegemer til beskyttelse af væv mod beskadigelse som følge af ioniseringsstråling
GB201304467D0 (en) 2013-03-12 2013-04-24 Tdeltas Ltd Compound for use in protecting skin
EP2984066B1 (en) 2013-03-14 2017-02-01 Oxford University Innovation Limited Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
WO2015003246A1 (en) * 2013-07-09 2015-01-15 Mcmaster University Combination of a statin with an inflammasome inhibitor
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR102682716B1 (ko) 2017-05-17 2024-07-08 비피지바이오, 인크. 수포성 표피박리증의 치료 및 예방에서 조효소 q10 제형의 용도
WO2018218287A1 (en) * 2017-05-29 2018-12-06 Woodlinda Pty Ltd Treatment and/or prevention of neuropathic symptoms associated with diabetes mellitus type ii
WO2019071353A1 (en) * 2017-10-13 2019-04-18 Exerkine Corporation USE OF XC-SYSTEM INHIBITOR FOR THE TREATMENT OF STATIN-INDUCED MYALGIA
KR102060722B1 (ko) * 2017-11-06 2020-02-11 연세대학교 산학협력단 스타틴에 의한 약물유해반응용 동물 모델 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2462312A1 (de) * 1974-03-04 1976-10-14 Nadrol Chemie Pharma Keizer Kg Arzneimittel zur behandlung von migraene-erkrankungen
SU988814A1 (ru) * 1979-11-20 1983-01-15 Филиал Всесоюзного научно-исследовательского химико-фармацевтического института им.Серго Орджоникидзе Соли оротовой кислоты и @ -аминокислот, предупреждающие развитие утомлени при физических нагрузках
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4911917A (en) * 1988-06-28 1990-03-27 Hauser-Kuhrts, Inc. Cholesterol-lowering combination comopsitions of magnesium salt and niacin
US4929437A (en) * 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
CA2007983C (en) * 1989-01-18 1996-12-10 Michael S. Brown Coenzyme q10 with hmg-coa reductase inhibitors
US5316765A (en) * 1989-09-07 1994-05-31 Karl Folkers Foundation For Biomedical And Clinical Research Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies
ES2146228T3 (es) * 1992-02-24 2000-08-01 Univ East Carolina Metodo para inhibir la carcinogenesis mediante tratamiento con deshidro-epiandrosterona y sus analogos.
BE1005939A6 (fr) * 1992-05-14 1994-03-15 Pirmez Thierry Dr Utilisation des sels de l'acide orotique comme tranporteurs preferentiels d'oligo-elements.
WO1993024650A1 (en) * 1992-05-28 1993-12-09 Monash University Therapeutic compositions
AT405477B (de) * 1996-04-03 1999-08-25 Norbert Mag Fuchs Kombinationspräparat
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245800B1 (en) * 1999-06-08 2001-06-12 Sigma-Tau Method of preventing or treating statin-induced toxic effects using L-carnitine or an alkanoyl L-carnitine
IT1317008B1 (it) * 2000-04-04 2003-05-26 Sigma Tau Healthscience Spa Integratore alimentare energizzante sulla muscolatura scheletrica eprotettivo sull'apparato cardiovascolare.
US6420342B1 (en) * 2000-05-08 2002-07-16 N.V. Nutricia Nutritional preparation comprising ribose and medical use thereof

Also Published As

Publication number Publication date
EP1343488A1 (en) 2003-09-17
AU2002223302B2 (en) 2006-08-31
DE60130023T2 (de) 2008-05-08
JP2010248230A (ja) 2010-11-04
US20100323981A1 (en) 2010-12-23
CA2429979A1 (en) 2002-06-06
ES2292643T3 (es) 2008-03-16
NZ526069A (en) 2006-11-30
JP4596734B2 (ja) 2010-12-15
CA2429979C (en) 2011-11-15
AU2330202A (en) 2002-06-11
DE60130023D1 (de) 2007-09-27
US20100144665A1 (en) 2010-06-10
HK1059044A1 (en) 2004-06-18
JP2004531468A (ja) 2004-10-14
EP1343488B1 (en) 2007-08-15
ATE369845T1 (de) 2007-09-15
US20040063661A1 (en) 2004-04-01
EP1343488A4 (en) 2005-05-04
WO2002043721A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
AUPR177300A0 (en) Therapeutic methods
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
NO974163L (no) Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
SI2017276T1 (sl) Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
WO2002018334A3 (en) Sodium channel modulators
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
GB2352972A (en) Use of dexmedetomidine for icu sedation
TW200639159A (en) Treatment of pain
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
NZ503027A (en) Use of rifamycin derivative for treating mastitis in a domestic animal
AUPR951101A0 (en) Method of treatment
WO2005035500A3 (en) Therapeutic agents useful for treating pain
AU2002211217A1 (en) Method of treating stroke
MXPA06000651A (es) Uso de derivados de indazol para el tratamiento de dolor neuropatico.
MXPA05006378A (es) Compuestos esteroides con actividad anti-tumoral.
MX2007006069A (es) Metodos para utilizar inhibidores de la fosfodiesterasa tipo v y para el tratamiento de insuficiencia cardiaca congestiva.
WO2003090737A3 (en) Methods and compositions for treatment of cancer pain

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 2330202

Country of ref document: AU